Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

Frank E. Mott, Christian T. Cable, Neeraj Sharma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We conducted a phase II single-institution trial in a homogenous patient population with advanced non-small-cell lung cancer to determine whether changing the carboplatin schedule in the carboplatin/gemcitabine doublet would enhance tolerability and/or results. Thirty patients with stage IIIB (with malignant effusion) or stage IV disease received gemcitabine 1100 mg/m2, days 1 and 8 plus carboplatin at an area under the curve of 5 on day 8. Cycles were repeated every 28 days, up to 6 cycles. A response rate of 10% was demonstrated (none complete), but an additional 45% of patients had stable disease. The median time to progression was 5.8 months and the median survival was 8.3 months. A 1-year survival rate of 27% and a 2-year survival rate of 16% were seen. The main nonhematologic toxicity was non-neutropenic infection. Thrombocytopenia occurred in 8 patients (27%; 7 grade 3, 1 grade 4). Carboplatin/gemcitabine with a day 8 administration of carboplatin is well tolerated with a similar survival to established platinum-based doublets.

Original languageEnglish (US)
Pages (from-to)174-176
Number of pages3
JournalClinical Lung Cancer
Volume5
Issue number3
DOIs
StatePublished - Nov 2003

Fingerprint

gemcitabine
Carboplatin
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Survival Rate
Survival
Platinum
Thrombocytopenia
Area Under Curve

Keywords

  • Cisplatin
  • Nephrotoxicity
  • Renal toxicity
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. / Mott, Frank E.; Cable, Christian T.; Sharma, Neeraj.

In: Clinical Lung Cancer, Vol. 5, No. 3, 11.2003, p. 174-176.

Research output: Contribution to journalArticle

Mott, Frank E. ; Cable, Christian T. ; Sharma, Neeraj. / Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. In: Clinical Lung Cancer. 2003 ; Vol. 5, No. 3. pp. 174-176.
@article{fbc9fc7b7bf1471e9a06d9fc69ed5ce0,
title = "Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer",
abstract = "We conducted a phase II single-institution trial in a homogenous patient population with advanced non-small-cell lung cancer to determine whether changing the carboplatin schedule in the carboplatin/gemcitabine doublet would enhance tolerability and/or results. Thirty patients with stage IIIB (with malignant effusion) or stage IV disease received gemcitabine 1100 mg/m2, days 1 and 8 plus carboplatin at an area under the curve of 5 on day 8. Cycles were repeated every 28 days, up to 6 cycles. A response rate of 10{\%} was demonstrated (none complete), but an additional 45{\%} of patients had stable disease. The median time to progression was 5.8 months and the median survival was 8.3 months. A 1-year survival rate of 27{\%} and a 2-year survival rate of 16{\%} were seen. The main nonhematologic toxicity was non-neutropenic infection. Thrombocytopenia occurred in 8 patients (27{\%}; 7 grade 3, 1 grade 4). Carboplatin/gemcitabine with a day 8 administration of carboplatin is well tolerated with a similar survival to established platinum-based doublets.",
keywords = "Cisplatin, Nephrotoxicity, Renal toxicity, Thrombocytopenia",
author = "Mott, {Frank E.} and Cable, {Christian T.} and Neeraj Sharma",
year = "2003",
month = "11",
doi = "10.3816/CLC.2003.n.030",
language = "English (US)",
volume = "5",
pages = "174--176",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

AU - Mott, Frank E.

AU - Cable, Christian T.

AU - Sharma, Neeraj

PY - 2003/11

Y1 - 2003/11

N2 - We conducted a phase II single-institution trial in a homogenous patient population with advanced non-small-cell lung cancer to determine whether changing the carboplatin schedule in the carboplatin/gemcitabine doublet would enhance tolerability and/or results. Thirty patients with stage IIIB (with malignant effusion) or stage IV disease received gemcitabine 1100 mg/m2, days 1 and 8 plus carboplatin at an area under the curve of 5 on day 8. Cycles were repeated every 28 days, up to 6 cycles. A response rate of 10% was demonstrated (none complete), but an additional 45% of patients had stable disease. The median time to progression was 5.8 months and the median survival was 8.3 months. A 1-year survival rate of 27% and a 2-year survival rate of 16% were seen. The main nonhematologic toxicity was non-neutropenic infection. Thrombocytopenia occurred in 8 patients (27%; 7 grade 3, 1 grade 4). Carboplatin/gemcitabine with a day 8 administration of carboplatin is well tolerated with a similar survival to established platinum-based doublets.

AB - We conducted a phase II single-institution trial in a homogenous patient population with advanced non-small-cell lung cancer to determine whether changing the carboplatin schedule in the carboplatin/gemcitabine doublet would enhance tolerability and/or results. Thirty patients with stage IIIB (with malignant effusion) or stage IV disease received gemcitabine 1100 mg/m2, days 1 and 8 plus carboplatin at an area under the curve of 5 on day 8. Cycles were repeated every 28 days, up to 6 cycles. A response rate of 10% was demonstrated (none complete), but an additional 45% of patients had stable disease. The median time to progression was 5.8 months and the median survival was 8.3 months. A 1-year survival rate of 27% and a 2-year survival rate of 16% were seen. The main nonhematologic toxicity was non-neutropenic infection. Thrombocytopenia occurred in 8 patients (27%; 7 grade 3, 1 grade 4). Carboplatin/gemcitabine with a day 8 administration of carboplatin is well tolerated with a similar survival to established platinum-based doublets.

KW - Cisplatin

KW - Nephrotoxicity

KW - Renal toxicity

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0347600552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347600552&partnerID=8YFLogxK

U2 - 10.3816/CLC.2003.n.030

DO - 10.3816/CLC.2003.n.030

M3 - Article

C2 - 14667273

AN - SCOPUS:0347600552

VL - 5

SP - 174

EP - 176

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -